Endevica Bio – The Cachexia Connection in Cancer
Dr. Kenneth Gruber, Founder and Chief Scientific Officer of Endevica Bio, a company focused on a new standard of care for cancer cachexia patients, discusses cachexia, also known as wasting syndrome, why it’s so prevalent in cancer, and the challenges of treating it. He talks about the current research and what might be on the horizon.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Key Takeaways
- Key Point: Kenneth Gruber, Founder and Chief Scientific Officer of Endevica Bio, a company focused on a new standard of care for cancer cachexia patients, discusses cachexia, also known as…
- Key Point: He talks about the current research and what might be on the horizon. Dr.
- Key Point: Kenneth Gruber, is the Founder, former CEO, and current Chief Scientific Officer of Endevica Bio.
- Key Point: He is a former National Institutes of Health Branch Chief, and spent decades in academia as an NIH-funded investigator.
- Key Point: He is the inventor on its six patents (3 US & 3 EU) which protect the intellectual property used to develop TCMCB07, as well as other peptide therapeutics.
Dr. Kenneth Gruber, is the Founder, former CEO, and current Chief Scientific Officer of Endevica Bio. He is a former National Institutes of Health Branch Chief, and spent decades in academia as an NIH-funded investigator. He is the inventor on its six patents (3 US & 3 EU) which protect the intellectual property used to develop TCMCB07, as well as other peptide therapeutics. He was the principal investigator on $4.5 million in NIH/NCI SBIR grants. These grants funded the development of the platform technology that produced Endevica’s lead drug-like melanocortin antagonist peptide (TCMCB07), and the basic drug development research.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


